Scholars Central

Conference abstractPublished 5 Sep 2016

Designing next-generation drug development in precision medicine

Authors: Dimitrios H Roukos

Ioannina University, Greece

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Breakthrough next-generation sequencing (NGS) systems and computational network methods shape two main strategies in drugs-discovery design. First, based on spatiotemporal genomic clones evolution, novel targetable drugs can be discovered against genome-wide alterations. Primary tumor multiregional NGS analysis before and after neoadjuvant treatment can reveal both intratumor heterogeneity (ITH) and clonal evolution in response to this systemic treatment. Moreover, an innovative noninvasive method of repeated circulating cell-free tumor DNA (ctDNA) followed NGS (ctDNA-NGS) can reveal subclones of plasma levels at different time points. This monitoring of these patients can not only predict therapeutic resistance-based metastatic relapse but also can result in novel drugs development to prevent with high precision metastatic progression. Ultimately, comparison of ITH with ctDNA-NGS in future rationally designed clinical trial opens new horizons of comprehensive intrapatient heterogeneity (IPH) identification that could substantially improve tumor responsiveness and overall survival. Second, in a more distant future, approach understanding of noncoding genome variation and functionality along with exploitation of transcriptional networks, drive the future development of highly effective drugs disrupting deregulated cancer transcriptional biocircuits. Although this ENCODE projectâÂ?Â? based research direction reflects the pragmatic molecular interaction networks underlying critical biological processes; much more work and time is required for understanding how structural and functional genome changes are underlying therapeutic resistance and relapse. This speech is concentrated on these two main drugs-development strategies. The first one continues to be based on simple, single-gene linear transcription dogma agents. The second innovative highly complex transcriptional networks-based approach aims to the future discovery of drugs disrupting aberrant cancer transcriptional biocircuits.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Medicinal Chemistry.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMedicinal Chemistry
  • SubjectChemistry
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Dimitrios H Roukos”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels